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HYPERHOMOSYSTEINEMIA AND CARDIOVASCULAR RISK PROFILE IN 
ISCHEMIC HEART DISEASE AND ACID PEPTIC DISEASE COMORBIDITY 
PATIENTS 
Chigozie C. Achugonye 3d Course student 
Supervisor - Dr. Albina Zharkova, MD, PhD 
Sumy State University 
Rationale. The study of common pathogenic mechanisms of comorbid course of ischemic heart 
disease (IHD) and acid related disorders (ARD) is an actual problem of modern medicine in terms of 
 prevention of cardiovascular complications. 
Aim of the study. To optimize the tactics of diagnosis and treatment of IHD when combined 
with the ARD of the gastrointestinal tract on a background of a long systemic intake of proton pump 
inhibitors (PPI). 
Material and methodsTo examine the effects of vitamin B supplementation on cardiovascular 
risk, we conducted a randomized study: 102 patients were examined, including 34 patients with 
isolated IHD, 33 patients with isolated ARD and 35 patients with comorbid pathology.  
Results.It was found that in patients with comorbid pathology were registered significantly 
lower levels of cyanocobalamin (237,1 ± 17,41 pg / ml) and higher levels of homocysteine (22,8 ± 
1.78 mmol / l) in blood plasma compared to the patients with isolated IHD (662,5±45,80 pg/ml; 
11,9±0,65 mmol/l, p<0.05). Hyperhomocysteinemia contributed to the development of atherogenic 
types dislipoproteinemia. Comorbidity for coronary heart disease and acid disorders accompanied by 
probable (p <0.05) increase in plasma levels of total cholesterol and low-density lipoproteins against 
decrease in high-density lipoproteins cholesterol levels compared to the isolated IHD (6.3%, 9.1% 
that 8.3%, respectively, p <0, 05). 
Тhe complex therapy that includes parenteral B12 supplementation leads to more effective 
correction of hyperhomocysteinaemia (26,1%, р<0,05) and dyslipidemia (total cholesterol - 14,9%, 
р<0,05; low-density lipoproteins - 22,3%, р<0,05), relative to the complex therapy without vitamin 
B12. 
Conclusion. Our results suggest that complex  ischemic heart disease therapy combined with 
vitamin B12 (but not vitamin B12 alone) may reduce serum lipids and hyperhomocysteinaemia in 
patients with comorbidity of IHD and ARD with long-term use of PPI.more effective. 
 
 
ADMINISTRATION OF L-CARNITINE IN PATIENTS SUFFERING FROM CHRONIC 
PANCREATITIS WITH UNDERLYING OBESITY 
S. Chobaniuk, V. Smandych 
О. Khukhlina MD., Ph.D. 
Higher State Educational Establishment of Ukraine "Bukovinian State Medical University" 
Introduction. Sickness rate of obesity has been 57% increased in recent years, and it occurs in 
80% of endocrine patients. Prevalence of chronic pancreatitis (CP) in patients with obesity constitutes 
from 45% to 80%. 
Objective: to investigate the effect of L-carnitine on clinical manifestation of CP in patients 
with obesity. 
Materials and methods: 60 patients suffering from CP of a mixed etiology, painful form, 
relapsing course in the phase of a moderate exacerbation with I degree of obesity have been examined. 
To define the efficacy of treatment two representative groups were formed. The control group (1K) 
received low-calorie diet, anti-secretory (proton pump inhibitor), spasmolytic agents during 1 month, 
and polyenzymatic (kreon 10-20 000 UN), hypolipidic (atorvastatin 20-40 mg) medicines during 90 
days. The main group also received a drinkable L-carnitine (steatel) per 1,0 (10 ml) twice a day during 
90 days. 
Results of the study: analysis of the suggested therapy effect for the patients with CP (O group) 
on the course of the diseases compared to K group revealed improved general condition, reduced 
signs of asthenic-vegetative, intoxication syndromes, dyspeptic signs in patients of O group on the 4-
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5 day, while in patients from K group–only on the 10th day. 2 weeks after initiation of therapy 
asthenic-vegetative syndrome of rather low intensity was found only in 3 persons (10,0%) of O group, 
while in K group it remained in 11 patients (36,7,0%). 
Conclusion: the application of L-carnitine in the treatment of patients with chronic pankreatitis 
and obesity promotes more rapid achievement of chronic pankreatitis' clinical remission, optimizing 
the lipid spectrum of the blood and reducing the inflammatory swelling of the pancreas. 
 
 
CARDIOVASCULAR COMPLICATIONS MARKERS IN HYPERTENSIVE PATIENTS 
WITH TYPE 2 DIABETES MELLITUS 
Dominas V., Chernatskaya O., Bessmertna R., Bolotnikova N., Gavrilenko A. 
Sumy City Clinical Hospital №1; Sumy State University 
The increase of blood pressure (BP) is the main risk factor of cardiovascular complications 
(CVC) for patients with type 2 diabetes mellitus (DM). There are also other markers of these 
complications such as glycated hemoglobin (HbA1с), dyslipidemia, characterized by atherogenic 
index (AI). 
The aim of our study was the determination of connection between markers of cardiovascular 
complications (CVC) for patients with type 2 DM and AH. 
Participants and methods. We involved 147 patients, treated in Sumy City Clinical Hospital 
№ 1, in our clinical trial. They were divided in two groups. Patients from the first (I) group had the 
AH and concomitant type 2 DM. Persons from the second (II) had only AH.  There are 87 patients in 
the I group and 60 persons in the II. The patients were more than 45 years old. The duration of type 
2 DM was (11±0,53) years old.  
The levels of HbA1с, general cholesterol (GCH) and different fractions of lipoproteins such as 
lipoproteins with high density (LPHD), lipoproteins with low (LPLD) and very low density (LPVLD) 
are obtained in blood serum. The atherogenic index was calculated with the help of mathematic 
method (AI = GCH – CH LPHD / CH LPHD).  
Student criteria (t) and the veracity of differences (p) are used for assessment results.   
Results. The mean levels of HbA1с were (6,8±0,21)%, (4,2±0,43)%,t = 5,43, p < 0,001  for 
participants from the I,II groups respectively. The mean levels of AI were (3,8±0,04), (3,1±0,02), t = 
15,65, p < 0,001 for participants from the I,II groups respectively. The levels of systolic BP were 
(156±0,45)mmHg, (143±0,66)mmHg, t = 16,27, p < 0,001 and of  diastolic – (105,3±0,6)mmHg, 
(94±0,43)mmHg respectively for patients with combination of AH and type 2 DM and for persons 
with AH. The higher levels of BP, HbA1с and more severe dyslipidemia are the characteristics of 
patients with AH and type 2 DM in comparing with hypertensive persons. 
Conclusions. There is the connection between factors of CVC such as AI, HbA1с, systolic and 
diastolic BP for patients with AH and type 2 DM. It is very important to define these markers for 
preventing end points and for improving treatment.  
 
 
X-ray STRUCTURE  CHARACTERISTIC OF DIABETIC OSTEOARTHROPATHY ON 
THE EARLY STAGES 
Melekhovets O.K., Chumachenko Ya.D., Nuryyev G.M., Kovchun V.Yu. 
Sumy State University, Family Medicine Department 
The aim of this paper is to study structural peculiarity of the bone on the early stages of diabetic 
osteoarthropathy. 
Materials and methods. Total of 67 patients with type 1 and 2 diabetes, who had diabetic foot 
0-III stage by Wagner`s classification, and the normal body mass index were included in the study. 
There were two groups of patients: 1 group included 33 patients with the duration of diabetes up to 
10 years, 2 group – 34 patients with the duration of diabetes more than 10 years. The control (0 group) 
included 30 practically healthy persons. The bone system investigation was done by the 
